Bristol-Myers Squibb Company (NYSE:BMY) previous close was $60.60 while the outstanding shares total 2.25B. The firm has a beta of 0.61. BMY’s shares traded higher over the last trading session, gaining 0.64% on 02/22/21. The shares fell to a low of $59.71 before closing at $60.99. Intraday shares traded counted 9.87 million, which was 14.51% higher than its 30-day average trading volume of 11.55M. The stock’s Relative Strength Index (RSI) is 46.27, with weekly volatility at 2.15% and ATR at 1.30. The BMY stock’s 52-week price range has touched low of $45.76 and a $67.16 high.
Investors have identified the Drug Manufacturers – General company Bristol-Myers Squibb Company as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $137.59 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Bristol-Myers Squibb Company (BMY) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For BMY, the company has in raw cash 14.55 billion on their books with 2.34 billion currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 30.19 billion total, with 19.08 billion as their total liabilities.
Having a look at the company’s valuation, the company is expected to record 7.99 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on BMY sounds very interesting.
Is the stock of BMY attractive?
In related news, EVP, Chief Information Officer, von Autenried Paul sold 3 shares of the company’s stock in a transaction that recorded on Nov 25. The sale was performed at an average price of 63.50, for a total value of 191. As the sale deal closes, the EVP, Chief Information Officer, von Autenried Paul now sold 20,000 shares of the company’s stock, valued at 1,255,000. Also, SVP,ChiefCompliance&EthicsOff., Dubow Adam sold 900 shares of the company’s stock in a deal that was recorded on Nov 24. The shares were price at an average price of 63.39 per share, with a total market value of 57,051. Following this completion of acquisition, the EVP, Research & Early Dev., VESSEY RUPERT now holds 13,421 shares of the company’s stock, valued at 823,244. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.10%.
11 out of 19 analysts covering the stock have rated it a Buy, while 6 have maintained a Hold recommendation on Bristol-Myers Squibb Company. 0 analysts has assigned a Sell rating on the BMY stock. The 12-month mean consensus price target for the company’s shares has been set at $75.13.